Product information and disease descriptionProduct description
Phase of product development
12 evidence topics · 16 sources
Summary
Mineralys Therapeutics submitted a New Drug Application (NDA) for lorundrostat to the FDA in December 2025 for “the treatment of hypertension in combination with other antihypertensive drugs”. The FDA accepted the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026. The company described the application as still under review in its third quarter 2026 results announcement and in its release on the Transform-HTN results presented on November 8, 2026. According to the company, the NDA includes the pivotal Launch-HTN (phase 3) and Advance-HTN (phase 2) trials, the Explore-CKD proof-of-concept trial, and the Transform-HTN open-label extension trial; the Explore-OSA trial was not part of the original application. In its 2026 Form 10-Q, the company described an advisory committee meeting as “not anticipated currently”. No FDA expedited program designation and no marketing application outside the United States was found. The company has stated no launch date; it describes its commercial preparations as on track for “launch upon approval”. In its third quarter 2025 results announcement, the company had planned the submission for “near the end of 2025 or during the first quarter of 2026”.
Regulatory status: Under review; NDA submitted December 2025, PDUFA target action date December 2026
Launch
No evidence found.
Commercial launch preparation: launch planned upon approval, no date stated
NDA submission, December 2025
Trials included in the NDA
Advisory committee meeting: not anticipated
FDA expedited program designations (Fast Track, Breakthrough Therapy, Priority Review)
No evidence found.
Marketing applications outside the United States
No evidence found.
NDA submission planned for late 2025 or the first quarter of 2026, November 2025, superseded in December 2025
Pivotal Launch-HTN and Advance-HTN topline results, March 2025
Phase 2 Target-HTN topline results, November 2022
First-in-human study by Tanabe, November 2016 to May 2017
“A four‐part, randomized, double‐blind, placebo‐controlled, first‐in‐human study was performed (single‐center in the Netherlands; November 16, 2016–May 01, 2017) to determine the safety, tolerability, PK, and PD of single ascending doses (SADs; part 1) and multiple ascending doses (MADs; part 2) of lorundrostat free base in a capsule in healthy participants” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote